The addition of GCGR agonism to GLP-1R agonism may therefore prove to be more efficacious in the treatment of type 2 diabetes and obesity, producing additive effects on energy intake and expenditure. Here, GCGR is linked to obesity due to melanocortin 4 receptor deficiency.